Engaging technology based on R&D conducted by the principals while at the University of Arizona, Proneurogen is structured around harnessing the power of peptides to find novel treatments for inflammation related brain disease, such as pain, cognitive impairment, memory loss, TBI and dementia. There is an increasing body of research to indicate brain inflammation as a key component of these diseases. The project being worked on by Proneurogen - PNA-5 - works as a natural anti-inflammatory and neuroprotectant by increasing brain blood flow, decreasing reactive oxygen species production and decreasing pro-inflammatory mechanisms which accelerate the progression of neurodegenerative disease. ProNeurogen's PNA-5 drug candidate improves the effects of the Angiotensin-(1-7) peptide by moving it across the blood-brain-barrier, increasing its half-life and improving its stability.